Carbamazepin-dihydrat | 85756-57-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: Carbamazepin-dihydrat
• 英文别名: carbamazepine dihydrate；CBZH；Carbamazepine hydrate；benzo[b][1]benzazepine-11-carboxamide;hydrate
• CAS: 85756-57-6
• 化学式: C₁₅H₁₂N₂O*2H₂O
• 分子量: 272.304
• InChiKey: XJVFVHLEBVSOAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.56
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  47.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  卡马西平 在 水 、 烟酰胺 作用下， 反应 0.1h， 生成 Carbamazepin-dihydrat
  参考文献：
  名称：

  In-line monitoring of cocrystallization process and quantification of carbamazepine-nicotinamide cocrystal using Raman spectroscopy and chemometric tools

  摘要：

  A cocrystallization process may involve several molecular species, which are generally solid under ambient conditions. Thus, accurate monitoring of different components that might appear during the reaction is necessary, as well as quantification of the final product. This work reports for the first time the synthesis of carbamazepine-nicotinamide cocrystal in aqueous media with a full conversion. The reactions were monitored by Raman spectroscopy coupled with Multivariate Curve Resolution - Alternating Least Squares, and the quantification of the final product among its coformers was performed using Raman spectroscopy and Partial Least Squares regression. The slurry reaction was made in four different conditions: room temperature, 40 degrees C, 60 degrees C and 80 degrees C. The slurry reaction at 80 degrees C enabled a full conversion of initial substrates into the cocrystal form, using water as solvent for a greener method. The employment of MCR-ALS coupled with Raman spectroscopy enabled to observe the main steps of the reactions, such as drug dissolution, nucleation and crystallization of the cocrystal. The PLS models gave mean errors of cross validation around 2.0 (% wt/wt), and errors of validation between 2.5 and 8.2 (% wt/wt) for all components. These were good results since the spectra of cocrystals and the physical mixture of the coformers present some similar peaks. (C) 2017 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.saa.2017.02.045

文献信息

• Taste masked pharmaceutical composition comprising pH sensitive polymer
  申请人：Kulkarni Gopalkrishna Mohan

  公开号：US20050136115A1

  公开（公告）日：2005-06-23

  The present invention discloses a substantially amorphous pharmaceutical composition comprising a drug that can exist in a variety of polymorphic forms and a pH sensitive polymer, which inhibits the crystallization of the drug during formulation and reconstitution. Polymers of higher molecular weight are more effective at lower loading, especially when the drug polymer matrix is prepared by the solvent evaporation or solvent extraction technique. The compositions used as dry syrups maintain bioavailability of the drug and effectively mask the taste of the drug when the composition is reconstituted.

  本发明公开了一种基本无定形的药物组合物，该组合物包含一种可以以多种多晶体形式存在的药物和一种对 pH 值敏感的聚合物，后者可以在配制和复溶过程中抑制药物结晶。分子量较高的聚合物在较低的负载量下更有效，特别是当药物聚合物基质是通过溶剂蒸发或溶剂萃取技术制备时。作为干糖浆使用的组合物可以保持药物的生物利用度，并在组合物重组时有效掩盖药物的味道。
• Orale Darreichungsformen mit verzögerter Abgabe
  申请人：CIBA-GEIGY AG

  公开号：EP0289977B1

  公开（公告）日：1993-09-15
• TASTE MASKED PHARMACEUTICAL COMPOSITION COMPRISING PH SENSITIVE POLYMER
  申请人：COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

  公开号：EP1694303A1

  公开（公告）日：2006-08-30
• US4857336A
  申请人：——

  公开号：US4857336A

  公开（公告）日：1989-08-15
• US5122543A
  申请人：——

  公开号：US5122543A

  公开（公告）日：1992-06-16